The company’s fourth quarter and full-year 2025 financial and operational results are preliminary and are subject to the completion of the company’s 2025 audit. Audited full-year 2025 and unaudited ...

RxSight offers a revolutionary adjustable IOL technology with superior outcomes and reduced side effects compared to traditional IOLs. The company's "razor-and-blade" business model, with the LAL and ...

Please provide your email address to receive an email when new articles are posted on . “I believe light adjustable technology could be the breakthrough we need in enhancement,” Thompson said at ...

The FDA gave its okay to RxSight’s implantable, light-adjustable intraocular lens that can make small adjustments that provide better vision for cataract surgery patients when they aren’t using ...

Calhoun Vision has been around a long, long time for a startup. It's been almost 20 years since its 1997 inception. But now it's got a massive infusion of $69 million that's following on the heels of ...

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors, and macroeconomic ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Current preoperative and intraoperative technologies are enabling better toric IOL implantation ...

Focal Point Vision, an ophthalmology practice with over 30 years of service in San Antonio, today announced its participation in the commercial release of the Light Adjustable Lens (LAL) from RxSight.

Wells Fargo upgraded RxSight Inc. (NASDAQ:RXST) from Equal Weight to Overweight on Monday, while raising its price target from $17 to $25 due to an attractive valuation at the current stock price.